-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PQ+bT5eY+2iIDQg5sHMTV6lzGL0Jt/G0ms364i9qeKzQelzeC8vNCkK8Ul9LJWEF Ldzq6lECMpAWgxZvV2DS7A== 0001104659-07-011955.txt : 20070216 0001104659-07-011955.hdr.sgml : 20070216 20070216165014 ACCESSION NUMBER: 0001104659-07-011955 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070216 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20070216 DATE AS OF CHANGE: 20070216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIMMUNE INC /DE CENTRAL INDEX KEY: 0000873591 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521555759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19131 FILM NUMBER: 07631964 BUSINESS ADDRESS: STREET 1: 35 W WATKINS MILL RD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 3014170770 MAIL ADDRESS: STREET 1: 35 W WATKINS MILL ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 a07-3198_28k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C.  20549

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

February 16, 2007 (February 16, 2007)

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-19131

 

52-1555759

(State or other jurisdiction of incorporation or organization)

 

(Commission File No.)

 

(I.R.S. Employer Identification No.)

 

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (301) 398-0000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 7.01               Regulation FD Disclosure.

MedImmune, Inc. (the “Company” or “MedImmune”) and its Board of Directors (the “Board”) welcome the views of all our shareholders and value their input.  On Wednesday, February 14, 2007, the Board received correspondence from David A. Katz, President of Matrix Asset Advisors, Inc. (“Matrix”), commenting on the Company’s quarterly results and suggesting that MedImmune consider a strategic sale.

MedImmune’s Board has since met and reviewed in detail the Matrix letter.  As part of that review, the Board took into consideration the Company’s business plan and recently reported results.  The Board also discussed the drivers of value for MedImmune’s shareholders, including, for example, the impact of the recent publication of a successful pivotal clinical trial with refrigerated FluMist showing its superior efficacy over the flu shot in children under five years of age in the New England Journal of Medicine.

After careful review of these and other considerations with its outside advisors, the Board has reaffirmed its conclusion that the best way for MedImmune to maximize value for its shareholders is to aggressively implement its business plan.

2



 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MedImmune, Inc.

 

 

 

 

 

 

Date: February 16, 2007

 

By:

 

/s/ William C. Bertrand, Jr. Esq.

 

 

 

 

 

William C. Bertrand Jr., Esq.

 

 

 

 

Senior Vice President, General Counsel &

Corporate Secretary

 

3


 -----END PRIVACY-ENHANCED MESSAGE-----